Clinical trial
Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in…
NCT00473954 · EGEN, Inc., Industry · Completed
Key facts
| NCT number | NCT00473954 |
|---|---|
| Title | Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer |
| Official title | A Phase 1, Open-Label, Dose Escalation Study of the Safety and Preliminary Efficacy of EGEN-001 in Combination With Carboplatin and Docetaxel in Women With Recurrent, Platinum-Sensitive, Epithelial Ovarian Cancer |
| Lead sponsor | EGEN, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms |
| Intervention type | Genetic |
| Interventions | EGEN-001 (phIL-12-005/PPC) |
| Enrollment | 13 |
| Start date | Apr 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | May 16, 2007 |
| Last update posted | Mar 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: